Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7847706 | 0.69 | — | — | |
| SCHEMBL7857549 | 0.65 | ALDH1A1 (0.31) | — | |
| SCHEMBL18519856 | 0.61 | CHEK1 (0.34) | CHEK1CCNB2CHEK2RAF1CDK1 | |
| SCHEMBL21296767 | 0.60 | PARP1 (0.35) | IDO1MAPTMAP2K1 | |
| SCHEMBL15328536 | 0.57 | ALDH1A1 (0.36) | — | |
| SCHEMBL5320280 | 0.56 | — | — | |
| SCHEMBL28099658 | 0.54 | — | — | |
| Hydrochloric Acid SCHEMBL5337157 | 0.54 | IDO1 (0.37) | IDO1MAPTMAP2K1 | |
| SCHEMBL1650480 | 0.54 | IDO1 (1.00) | IDO1MAPTMAPK1MAP2K1 | |
| SCHEMBL24404193 | 0.54 | IDO1 (0.52) | IDO1MAPTMAPK1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381335-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | SYNTHORX INC (US) | 2023-11-30 | — | — | US | disclosed |
| US-9422564-B2 | Immunostimulatory sequence oligonucleotides and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2640426-B1 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | SELECTA BIOSCIENCES INC (US) | 2016-02-03 | — | — | EP | disclosed |
| US-9228184-B2 | Human toll-like receptor inhibitors and methods of use thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | DYNAVAX TECHNOLOGIES CORPORATION | 2015-10-22 | — | — | US | disclosed |
| US-20150132293-A1 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | TRISALUS LIFE SCIENCES, INC. | 2015-05-14 | — | — | US | disclosed |
| US-9028845-B2 | Chimeric immunomodulatory compounds and methods of using the same-IV | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2015-05-12 | — | — | US | disclosed |
| US-8962579-B2 | Methods and compositions for inhibition of immune responses and autoimmunity | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2015-02-24 | — | — | US | disclosed |
| US-8940310-B2 | Methods of treatment using TLR7 and/or TLR9 inhibitors | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-8871732-B2 | Immunostimulatory sequence oligonucleotides and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090148479-A1 | METHODS OF MODULATING AN IMMUNE RESPONSE USING IMMUNOSTIMULATORY SEQUENCES AND COMPOSITIONS FOR USE THEREIN | DYNAVAX TECHNOLOGIES CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-20090068208-A1 | LONG TERM DISEASE MODIFICATION USING IMMUNOSTIMULATORY OLIGONUCLEOTIDES | DYNAVAX TECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-7479285-B1 | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2009-01-20 | — | — | US | disclosed |
| US-20090017075-A1 | Immunomodulatory compositions, methods of making, and methods of use thereof | DYNAVAX TECHNOLOGIES CORPORATION | 2009-01-15 | — | — | US | disclosed |
| US-20080207550-A1 | IMMUNOMODULATORY POLYNUCLEOTIDES AND METHODS OF USING THE SAME | TRISALUS LIFE SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080181909-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | DYNAVAX TECHNOLOGIES CORPORATION | 2008-07-31 | — | — | US | disclosed |
| US-20070258994-A1 | Immunomodulatory formulations and methods for use thereof | DYNAVAX TECHNOLOGIES CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20030130217-A1 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation | TEL AVIV SOURASKY MEDICAL CENTER (IL) | 2003-07-10 | — | — | US | disclosed |
| US-20030119773-A1 | Method for enhancing an immune response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERIVES (DHHS), U.S.GOVERNMENT | 2003-06-26 | — | — | US | disclosed |
| US-20030078223-A1 | Compositions and methods for modulating an immune response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181909-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | TSLP, CD74, MICA | IDO1 81/4885MAPT 4801/4885CHEK1 4318/4885 |
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | ICOS, CD47, IL2 | IDO1 69/4885MAPT 3989/4885CHEK1 3671/4885 |
| US-20230381335-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | IL2, PDCD1LG2, CD274 | IDO1 512/4885MAPT 1905/4885CHEK1 1480/4885 |
| US-20150132293-A1 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | TLR3, TLR9, CD74 | IDO1 159/4885MAPT 4727/4885CHEK1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.